Ahmed S, Glover P, Taylor J, et al. - Given that the latest update of the World Health Organization’s classification of lymphoid neoplasms recommends cell‐of‐origin subclassification of diffuse large B cell lymphoma (DLBCL) into activated B cell‐like, germinal centre B cell‐like and unclassified or type III by gene expression profiling, but there exists no accepted gold standard method or dataset for this classification, therefore, researchers performed a comparison of classification results utilizing gene expression data for 68 formalin‐fixed paraffin‐embedded DLBCL samples measured on four different gene expression platforms (Illumina wG‐DASL arrays, Affymetrix PrimeView arrays, Illumina TrueSeq RNA sequencing and the HTG EdgeSeq DLBCL Cell of Origin Assay EU employing an established platform agnostic classification algorithm (DAC) and the classifier native to the HTG platform, which is CE marked for in vitro diagnostic use (CE‐IVD). Experts found that a high level of concordance was shown by classification methods and platforms, with agreement in at least 80% of cases and increasing to much higher levels for classifications of high confidence. Overall, cell‐of‐origin classification by gene expression profiling on different platforms was concluded to be robust, and findings highlighted the importance of the use of the confidence value alongside the classification result in clinical applications.